News
-
Insmed has announced that a Phase 2b study of treprostinil palmitil inhalation powder (TPIP) in patients with pulmonary arterial hypertension met its primary endpoint, demonstrating a 35% reduction from baseline in pulmonary vascular resistance. The company said… Read more . . .
-
Startup Mosanna Therapeutics announced that it has closed a $80 million Series A financing that will fund Phase 2 development of the company’s MOS118 nasal spray for the treatment of obstructive sleep apnea. Mosanna also announced the… Read more . . .
-
Transpire Bio announced that it has acquired an exclusive license to develop Suzhou Intragrand Pharma’s ITG-1052, a PDE4 inhibitor, as an inhaled therapeutic for the treatment of idiopathic pulmonary fibrosis and other respiratory diseases. The… Read more . . .
-
Leyden Laboratories has announced a €20 million venture debt financing deal with the European Investment Bank, with funds intended to support development of Leyden Labs’ antiviral nasal sprays, including PanFlu. The investment falls under the… Read more . . .
-
According to Cessatech, the Phase 2/3 Pediatric Study 0202 of the company’s CT001 sufentanil / ketamine nasal spray in children with severe pain met its primary endpoint, with more than half of patients reporting pain… Read more . . .
-
RDD Europe 2025, which took place in Estoril, Portugal May 6-9, welcomed approximately 490 delegates and 70 exhibitors from around the world to a meeting that focused on overcoming complex problems in order to advance inhaled… Read more . . .
-
According to Savara, the FDA has issued an RTF letter in response to the company’s BLA for Molbreevi molgramostim inhalation solution for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP), citing insufficient CMC data. Savara completed… Read more . . .
-
At the end of March 2025, the FDA accepted Liquidia Corporations’s resubmitted NDA for Yutrepia dry powder treprostinil for inhalation for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung… Read more . . .
-
Nuance Pharma has announced that the Phase 3 ENHANCE-CHINA study of nebulized ensifentrine in patients with COPD has met its primary endpoint. The company obtained the rights to ensifentrine, a PDE3/PDE4 inhibitor, in China, Macau, Taiwan,… Read more . . .
-
According to Ritedose Pharmaceuticals, the FDA has approved an ANDA for the company’s generic albuterol sulfate inhalation solution, 0.5%. In April 2023, Ritedose announced that it had begun manufacturing 5 mg/ml albuterol sulfate inhalation solution… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden